| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/17/2003 | US20030133893 Compositions and methods for treating skin ailments |
| 07/17/2003 | US20030133880 Powdery pharmaceutical compositions for inhalation |
| 07/17/2003 | US20030133879 Therapeutic composition for pulmonary delivery |
| 07/17/2003 | US20030133876 Preparation of further diagnostic agents |
| 07/17/2003 | US20030133872 Radiopharmaceutical agent for the treatment of early stage cancer |
| 07/17/2003 | CA2473081A1 Use of phospholipids in peritoneal dialysis |
| 07/17/2003 | CA2472937A1 Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| 07/17/2003 | CA2472917A1 Dendritic encapsulation of active agents |
| 07/17/2003 | CA2472383A1 Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| 07/17/2003 | CA2472154A1 Use of antibodies against the muc18 antigen |
| 07/17/2003 | CA2471948A1 Novel pharmaceutical dosage forms and method for producing same |
| 07/17/2003 | CA2471936A1 Methods for using anti-muc18 antibodies |
| 07/17/2003 | CA2471868A1 Methods of generating multispecific, multivalent agents from vh and vl domains |
| 07/17/2003 | CA2471849A1 Antibodies against the muc18 antigen |
| 07/17/2003 | CA2471572A1 Taxane based compositions and methods of use |
| 07/17/2003 | CA2471490A1 Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders |
| 07/17/2003 | CA2471431A1 Compositions and methods for the diagnosis and treatment of tumor |
| 07/17/2003 | CA2471211A1 Drug delivery system for sustained delivery of glipizide |
| 07/17/2003 | CA2470495A1 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
| 07/17/2003 | CA2469480A1 Use of biomolecular targets in the treatment and visualization of tumors |
| 07/16/2003 | EP1327628A2 Lipidization of hydrophilic molecules |
| 07/16/2003 | EP1327463A1 Gel comprising Cetirizine and Loratadine for topical application |
| 07/16/2003 | EP1327454A2 Method of treatment with medical agents |
| 07/16/2003 | EP1327453A1 Stable taurolidine electrolyte solutions |
| 07/16/2003 | EP1327451A1 Adjuvants for vaccines |
| 07/16/2003 | EP1327449A1 Remedies for ischemic diseases |
| 07/16/2003 | EP1327446A1 Controlled release oxycodone compositions |
| 07/16/2003 | EP1327445A1 Controlled release oxycodone compositions |
| 07/16/2003 | EP1327441A1 Chewing gum composition for eliminating nicotine, containing plant extracts and polyphenols such as catechin or quercetin |
| 07/16/2003 | EP1327434A1 Nanoemulsion comprising metabolites of ginseng saponin and a skin-care composition for anti-aging containing the same |
| 07/16/2003 | EP1327149A2 Methods of high-throughput screening for internalizing antibodies |
| 07/16/2003 | EP1326894A2 Novel tumor-associated marker |
| 07/16/2003 | EP1326892A2 Compositions that inhibit proliferation of cancer cells |
| 07/16/2003 | EP1326838A1 Novel crystalline forms of a factor xa inhibitor |
| 07/16/2003 | EP1326825A2 Compounds and compositions for delivering active agents |
| 07/16/2003 | EP1326645A1 Complexes for transferring nucleic acids into cells |
| 07/16/2003 | EP1326644A1 Absorption enhancers |
| 07/16/2003 | EP1326633A1 Composition comprising immunogenic microparticles |
| 07/16/2003 | EP1326631A1 Methods for treating endocrine disorders |
| 07/16/2003 | EP1326624A1 Method for producing phyllanthus extracts |
| 07/16/2003 | EP1326608A1 Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers |
| 07/16/2003 | EP1326607A1 Pharmaceutical compositions containing oxapenem-3-carboxilic acids |
| 07/16/2003 | EP1326600A2 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 07/16/2003 | EP1326599A2 Treatment and prophylaxis of diseases and infections of pigs and poultry with aivlosin |
| 07/16/2003 | EP1326595A2 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders |
| 07/16/2003 | EP1326590A2 Patch comprising diclofenac |
| 07/16/2003 | EP1326589A2 Nanoparticles |
| 07/16/2003 | EP1326587A2 Hydrogel-driven drug dosage form |
| 07/16/2003 | EP1326585A2 Method for producing powdery formulations |
| 07/16/2003 | EP1326583A1 Medication delivery devices |
| 07/16/2003 | EP1326500A1 Encased food product with contrasting components |
| 07/16/2003 | EP1326496A1 A release composition and method of preparation |
| 07/16/2003 | EP1235579B1 Pharmaceutical compositions comprising trimegestone |
| 07/16/2003 | EP1221840B1 Active material within hydrogel microbeads |
| 07/16/2003 | EP1214058B1 Method to obtain microparticles |
| 07/16/2003 | EP1191947A4 Methods for treating avm' using radioactive compositions |
| 07/16/2003 | EP1112066B1 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor |
| 07/16/2003 | EP1084172B1 Polyamino acid vesicles |
| 07/16/2003 | EP0934059B1 Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules |
| 07/16/2003 | EP0830137B1 Ionic molecular conjugates of n-acylated derivatives of poly(2-amino-2-deoxy-d-glucose) and polypeptides |
| 07/16/2003 | EP0743856B1 Antigen-based heteropolymers for treating autoimmune diseases |
| 07/16/2003 | EP0587744B1 Chewable drug-delivery composition |
| 07/16/2003 | CN1430533A Emulsifiers |
| 07/16/2003 | CN1430521A Solid dispersion system of Pranlukast with improved dissolution, and the preparing method thereof |
| 07/16/2003 | CN1430520A Method of stabilizing preparation |
| 07/16/2003 | CN1430513A Topical formulations for the transdermal delivery of niacin and method of treating hyperlipidemia |
| 07/16/2003 | CN1430511A Method of improving survival of patients |
| 07/16/2003 | CN1430510A Novel formulations of alpha 2,4-disulforphenyl-N-tert-butylnitrone |
| 07/16/2003 | CN1430509A Method for controlling septemia shock |
| 07/16/2003 | CN1430508A Novel composition |
| 07/16/2003 | CN1430506A Process for producing microsphere |
| 07/16/2003 | CN1430505A Microspheres for active embolization |
| 07/16/2003 | CN1430504A Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into biological environmentat from polymer matrix |
| 07/16/2003 | CN1430503A O/W emulsion |
| 07/16/2003 | CN1430502A Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| 07/16/2003 | CN1430501A Preparation of injectable suspensions having improved injectabity |
| 07/16/2003 | CN1429605A Drug composition for preventing and treating prospermia and/or sexual excitation hypersensitivity |
| 07/16/2003 | CN1429547A Coronary artery skeleton medicinal coating for preventing restenosis of blood vessel |
| 07/16/2003 | CN1429545A Dimethyl silicone oil used as weighting reinforcing agent |
| 07/16/2003 | CN1114589C Method of rendering organic compounds soluble in fatty systems, complexes of such compounds and various applications of complexes |
| 07/16/2003 | CN1114448C Gelling cosmetic and/or skin using composition containing dissolvant and hollow particles |
| 07/16/2003 | CN1114408C Oral medicinal composition containing pyridazinone compound |
| 07/16/2003 | CN1114405C Gastroprotected omerprazole microgranules, method for obtaining same and pharmaceutical preparation |
| 07/16/2003 | CN1114400C Biocompatible compounds for pharmaceutical drug delivery systems |
| 07/16/2003 | CN1114399C Ophthalmic composition containing ion sensitive hy drophilic polymer and inorganic salt in ratio which gives low viscosity |
| 07/15/2003 | US6593458 Antibody for use in the treatment of cancer |
| 07/15/2003 | US6593376 Two hydrophilic and at least two hydrophobic groups by reacting an olefinic substrate having at least two double bonds with an organic hydroperoxide to form an oxirane ring, opening, the oxirane ring with an alcohol in the presence of a |
| 07/15/2003 | US6593370 Topical capsaicin preparation |
| 07/15/2003 | US6593344 These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum and autoimmune diseases |
| 07/15/2003 | US6593320 Flocculated suspension of megestrol acetate |
| 07/15/2003 | US6593318 Flocculated suspension of megestrol acetate |
| 07/15/2003 | US6593317 Progestin therapy for maintaining amenorrhea |
| 07/15/2003 | US6593309 Contacting a sample containing sperm with a solution comprising a polysaccharide containing arabinose, galactose and/or hexuronic acid (PCAGH) to form a mixture, wherein the PCAGH is not arabinogalactan; separating sperm from the sample |
| 07/15/2003 | US6593308 Targeted drug delivery with a hyaluronan ligand |
| 07/15/2003 | US6593296 Stabilized growth hormone formulation and method of preparation thereof |
| 07/15/2003 | US6593294 Coagulation factor VIII and substantially neutral colloidal particles comprising 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer for treatment of hemophilia |
| 07/15/2003 | US6593292 Amidine and/or guanidine substituted peptoid and drug conjugates for drug delivery across endo/epithelial tissue |
| 07/15/2003 | US6592907 Treating an eye infections; cleansing a contact lens in place on an eye |
| 07/15/2003 | US6592903 Redispersibility upon administration to human or animal |
| 07/15/2003 | US6592902 Controlled release eplerenone compositions |